GLP1R and MODY: In addition, only MODY 3–5 have been reported to be treated with meglitinides [25], glucagon-like peptide-1 receptor agonists [26], sodium-glucose co-transporter-2 inhibitors [27], metformin [28], dipeptidyl peptidase-4 inhibitors [29], or repaglinide [30] in case reports (Table 2).